Sugi Predict

Sugi Predict / Compounds / SCHEMBL131267

SCHEMBL131267

SCHEMBL131267

Cc1sc(N)nc1-c1ccc(F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.65
▸ MPL P40238 2/20 0.59
▸ MYC P01106 2/20 0.54
▸ WDR5 P61964 2/20 0.54
▸ CD274 Q9NZQ7 1/20 0.53
▸ MAPT P10636 2/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ XBP1 P17861 1/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ ALDH1A1 P00352 5/20 0.50
▸ PKM P14618 1/20 0.50
▸ RAB9A P51151 2/20 0.46
▸ ALOX5 P09917 1/20 0.46
▸ TGFBR1 P36897 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ ALOX12 P18054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2303869 0.85 SMN1; SMN2 (0.70) SMN1; SMN2MPLMYCWDR5CD274
SCHEMBL30257627 0.81 SMN1; SMN2 (0.65) SMN1; SMN2MPLMYCWDR5CD274
SCHEMBL1802030 0.81 SMN1; SMN2 (0.65) SMN1; SMN2MPLMYCWDR5CD274
SCHEMBL11480686 0.81 SMN1; SMN2 (0.65) SMN1; SMN2MPLMYCWDR5CD274
SCHEMBL330423 0.81 SMN1; SMN2 (0.64) SMN1; SMN2MPLCD274MAPTNPSR1
SCHEMBL29272745 0.81 MYC (0.57) SMN1; SMN2MPLMYCWDR5MAPT
SCHEMBL8188473 0.81 ALDH1A1 (0.61) SMN1; SMN2MPLMYCWDR5NPSR1
SCHEMBL31311390 0.81 MPL (0.71) SMN1; SMN2MPLCD274MAPTNPSR1
SCHEMBL9572144 0.79 ALDH1A1 (0.51) SMN1; SMN2MPLMYCWDR5MAPT
SCHEMBL8069327 0.79 MAPT (0.68) SMN1; SMN2MYCWDR5MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115433958-B Electrochemical synthesis method of 2-aminothiazole compound 北京工商大学 2025-02-21 — — CN disclosed
CN-115433958-A Electrochemical synthesis method of 2-aminothiazole compound 北京工商大学 2022-12-06 — — CN disclosed
CN-110526929-A Heteroaromatic compounds, its pharmaceutical composition and its application GUANGZHOU HENOVCOM BIOSCIENCE CO LTD 2019-12-03 — — CN disclosed
CN-109384803-A ATX inhibitor and its preparation method and application 广州市恒诺康医药科技有限公司 2019-02-26 — — CN disclosed
CN-105143221-B Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders 加拉帕戈斯股份有限公司 2017-06-09 — — CN disclosed
EP-2384320-B1 PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2015-03-04 — — EP disclosed
US-8629157-B2 Pyrrolidine compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-14 — — US disclosed
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 — — EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 — — US disclosed
US-20120283255-A1 UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR GALAPAGOS SASU (FR) 2012-11-08 — — US disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 — — EP disclosed
US-20100240889-A1 Urea Derivatives Methods For Their Manufacture And Uses Thereof PROSKELIA SAS (FR) 2010-09-23 — — US disclosed
US-20100240889-A1 Urea Derivatives Methods For Their Manufacture And Uses Thereof PROSKELIA SAS (FR) 2010-09-23 — — US disclosed
US-20100240889-A1 Urea Derivatives Methods For Their Manufacture And Uses Thereof PROSKELIA SAS (FR) 2010-09-23 — — US disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 — — WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 — — US disclosed
CN-101238120-A Urea derivatives, process for their preparation and their use GALAPAGOS SAS (FR) 2008-08-06 — — CN disclosed
EP-1874765-A2 UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF Proskelia SAS (FR) 2008-01-09 — — EP disclosed
WO-2006117211-A2 UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF PROSKELIA SAS (FR) 2006-11-09 — — WO disclosed
EP-0538097-A1 Naphthalene-1-acetic-acid derivatives, their preparation and their use as pesticides ROUSSEL UCLAF (FR) 1993-04-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 SMN1; SMN2 4749/4885MPL 1091/4885MYC 2629/4885
US-20120283255-A1 UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR UTS2R, UGP2, SLC14A1 SMN1; SMN2 4565/4885MPL 4599/4885MYC 3544/4885
US-20100240889-A1 Urea Derivatives Methods For Their Manufacture And Uses Thereof UGP2, UTS2R, UMPS SMN1; SMN2 4052/4885MPL 4727/4885MYC 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.